NUR 521 AVD PHARM BLUEPRINT EXAM 1
FINAL EXAMINATION TEST PAPER 2026
FULL ANSWERS GRADED A+
⩥ Rivastigmine (Exelon) mechanism of action. Answer:
Acetylcholinesterase and butyrylcholinesterase inhibitor that forms a
carbamoylate complex with the enzymes
⩥ Galantamine (Razadyne) mechanism of action. Answer:
Acetylcholinesterase inhibitor and non-potentiating ligand of nicotinic
receptors
⩥ Primary use of Donepezil, Rivastigmine, and Galantamine. Answer:
Mild to moderate Alzheimer's disease
⩥ Toxicities of cholinesterase inhibitors (donepezil, rivastigmine,
galantamine). Answer: Diarrhea, nausea, vomiting, cramps, anorexia,
vivid dreams
⩥ Memantine (Namenda) mechanism of action. Answer: NMDA
receptor antagonist that decreases excitotoxic NMDA channel activation
⩥ Clinical use of Memantine. Answer: Moderate to severe Alzheimer's
disease
, ⩥ Common toxicities of Memantine. Answer: Tiredness, dizziness,
confusion, sleepiness, vomiting, constipation
⩥ Aducanumab (Aduhelm) mechanism of action. Answer: Monoclonal
antibody against aggregated soluble and insoluble forms of beta-amyloid
⩥ Clinical effect of Aducanumab. Answer: Reduces beta-amyloid load
and plaques in the brain
⩥ Aducanumab pharmacokinetics. Answer: 10 mg/kg IV infusion over 1
hour every 4 weeks
⩥ Aducanumab toxicities. Answer: Amyloid-related imaging
abnormalities (ARIA): edema, headache, microhemorrhage, superficial
siderosis, and falls
⩥ Lecanemab (Leqembi) mechanism of action. Answer: Humanized
IgG1 monoclonal antibody that binds soluble Aβ protofibrils
⩥ Clinical use of Lecanemab. Answer: Mild cognitive impairment
(MCI) to mild Alzheimer's disease
FINAL EXAMINATION TEST PAPER 2026
FULL ANSWERS GRADED A+
⩥ Rivastigmine (Exelon) mechanism of action. Answer:
Acetylcholinesterase and butyrylcholinesterase inhibitor that forms a
carbamoylate complex with the enzymes
⩥ Galantamine (Razadyne) mechanism of action. Answer:
Acetylcholinesterase inhibitor and non-potentiating ligand of nicotinic
receptors
⩥ Primary use of Donepezil, Rivastigmine, and Galantamine. Answer:
Mild to moderate Alzheimer's disease
⩥ Toxicities of cholinesterase inhibitors (donepezil, rivastigmine,
galantamine). Answer: Diarrhea, nausea, vomiting, cramps, anorexia,
vivid dreams
⩥ Memantine (Namenda) mechanism of action. Answer: NMDA
receptor antagonist that decreases excitotoxic NMDA channel activation
⩥ Clinical use of Memantine. Answer: Moderate to severe Alzheimer's
disease
, ⩥ Common toxicities of Memantine. Answer: Tiredness, dizziness,
confusion, sleepiness, vomiting, constipation
⩥ Aducanumab (Aduhelm) mechanism of action. Answer: Monoclonal
antibody against aggregated soluble and insoluble forms of beta-amyloid
⩥ Clinical effect of Aducanumab. Answer: Reduces beta-amyloid load
and plaques in the brain
⩥ Aducanumab pharmacokinetics. Answer: 10 mg/kg IV infusion over 1
hour every 4 weeks
⩥ Aducanumab toxicities. Answer: Amyloid-related imaging
abnormalities (ARIA): edema, headache, microhemorrhage, superficial
siderosis, and falls
⩥ Lecanemab (Leqembi) mechanism of action. Answer: Humanized
IgG1 monoclonal antibody that binds soluble Aβ protofibrils
⩥ Clinical use of Lecanemab. Answer: Mild cognitive impairment
(MCI) to mild Alzheimer's disease
